Sulfonylurea (SU) derivatives exert their hypoglycemic ef fect by blockade of adenosine-S'-triphosphate-sensitive potassium (KA T P) channels in the beta cell of the pancreas. Inter estingly, Katp channels also occur in the cardiovascular system, where they are thought to play an important role in cardiopro tective mechanisms against ischemia. We have recently shown that the classical second generation SU-derivative gllbenclamide is able to block vascular KA T P channels in man, whereas the newly developed second generation derivative glimepiride was devoid of this property. The aim of this study was to determine whether the first generation SU derivative tolbutamide has KA T P channel blocking properties in humans. In a group of 12 healthy male non-smoking volunteers, w e investigated whether therapeutic concentrations of tolbutamide were able to inhibit the forearm vasodilation in response to the infusion of the KA T P channel open ing drug diazoxide into the brachial artery. Changes in forearm blood flow were recorded by venous occlusion mercury-in-silastic strain-gauge plethysmography. Diazoxide alone increased the forearm blood flow ratio dose-dependently by ultimately 691 ± 198%. A second diazoxide infusion in the presence of tolbu tamide revealed a comparable vasodilator response with a per centage increase in forearm blood flow ratio of ultimately 542 ± 111 %. This response did not differ from the vasodilator response to diazoxide alone. The present study shows that therapeutic concentrations of tolbutamide are not able to attenuate the va sodilation caused by the KA T P channel opener diazoxide in man. When compared with published data on second generation SUderivatives, tolbutamide shows an intermediate position be tween glibenclamide (with significant blockade of vascular KA T P channels) versus glimepiride (with no blockade at all). It remains to be determined whether these acute effects of SU derivatives on pharmacological opening of forearm vascular KA T P channels can be extrapolated to the chronic effects of these drugs on ischemia-mediated opening of myocardial KA T P channels during treatment of NIDDM patients.
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Introduction
Since the introduction of sulfonylurea (SU) derivatives, studies of these agents have been focused on metabolic effects in patients with non-insulin dependent diabetes mellitus (NIDDM) (11, 17) . Both the first generation SU derivative tolbu tamide and the second generation SU derivative glibenclamide induce their pharmacological effect by blockade of adenosine-5'-triphosphate-sensitive potassium (KA TP) channels in the beta cell of the pancreas. This ultimately promotes an influx of cal cium with subsequent stimulation of insulin release (9) . In the last two decades, an increasing interest in the extra-pancreatic effects of these drugs has been reported (1, 3, 19, 21, 22, 24) . In animal models, SU derivatives have been shown to attenuate the vasodilator response to an ischemic stimulus (2) , and to abolish the protective effects of myocardial ischemic precon ditioning (12, 26) . In these preparations, glibenclamide has even been shown to increase myocardial infarct size (25) . In theory, the aforementioned observations may suggest harmful cardiovascular effects of SU derivatives when used under con ditions of ischemia in patients with NIDDM. In 1970 the Uni versity Group Diabetes Program (UGDP) study first reported possible adverse cardiovascular effects of SU derivatives in man (27) . Although this study has been extensively criticized, recent observations on the interaction between SU-derivatives and human vascular I<A T P-channels may be of great importance with respect to this issue (5).
We have just shown that the classical second generation SU derivative glibenclamide can interact with vascular I<A T P chan nels in man at therapeutic concentrations (5) . In theory, this interaction may have contributed to the cardiovascular adverse effects as reported in the UGDP-study (5) . However, it has to be emphasized that tolbutamide and not glibenclamide was used in the UGDP-study. Almost all experimental animal stu dies on cardiovascular effects of SU-derivatives have used glibenclamide, and not tolbutamide. Therefore, we conducted a study to evaluate whether therapeutic concentrations of tolbutamide are able to block vascular KA TP-channels in humans. This question was investigated by recording the in teraction of tolbutamide with the KA TP-channel opening drug diazoxide. The data will be discussed in relation to previously published original observations on glibenclamide (5) . Data on the newly developed second generation SU-derivative glimepiride wil also be discussed, since this agent seems to be devoid of I<A T P-channei blocking properties (5, 14, 15) .
Methods
This study investigated the putative inhibitoiy effects of tolbu tamide on the Katp channel-mediated vasodilation by di azoxide. To address this issue, the perfused forearm technique was used (28) . The study protocol was approved by the local ethics committee, and all 12 participants gave written in formed consent before entering the study. All experiments were performed in healthy male non-smoking volunteers with a normal history, physical examination, and blood pressure. The characteristics of the volunteers are listed in Table 1 . Each volunteer participated in only one experiment and was in structed to abstain from caffeine-containing beverages and al cohol at least 24 hours before the experiment. Furthermore, they were asked to eat a light meal two hours before the ex periment was started and then to abstain from further food intake until after the experiment Forearm volume was measured by water displacement. The experiments were per formed with the subjects in the supine position in a quiet temperature controlled room (22 °C), to ensure that forearm blood flow (FBF) predominantly reflected forearm muscle per fusion (8) . Data are presented as means (± SD). *Sphygmomanometrically obtained blood pressure after 5 min supine rest
The effects of tolbutamide on the dia2oxide-mediated vasodi lation were studied. A cannula was inserted into the brachial artery (Angiocath, 20 gauge, Deseret Medical Inc., Becton Dick inson and Comp., Sandy, Utah). Antecubital veins of the left and the right arm were also cannulated. After an equilibration pe riod of 45 minutes, a 35 minute intraarterial infusion of placebo (saline) was started. After 10 minutes of saline infusion, base line measurements of blood pressure, heart rate, and bilateral FBF were taken during the concomitant intraarterial infusion of placebo. Then*a dose-response curve of the vasodilator ef fects of diazoxide was made (three intraarterial dosages: 0.25, 0.75, 2.25 mg/min/dl using an automated syringe infusion pump) (type STC-521, Terumo Corp., Tokyo, Japan). Blood pres sure was measured via the intraarterial line using a Hewlett Packard monitor (type 7853B, Hewlett Packard GmbH, Böblin gen, Germany). Forearm blood flow was measured by ECG-triggered venous occlusion mercury-in-silastic strain-gauge plethysmography (Hokanson EC4, D.E. Hokanson, Inc., Issaquah, Washington, USA). During all recordings of the FBF, the hand circulation was completely occluded by a wrist cuff in flated 100 mmHg above the systolic blood pressure to be sure that measurements only referred to the forearm skeletal muscle vascular bed (16) . After a subsequent equilibration of 60 minutes to allow parameters to return towards baseline levels, baseline values were again recorded during concomi tant intraarterial infusion of placebo. Then a second dose-re sponse curve was made in all subjects, but now with concom itant intraarterial infusion of tolbutamide instead of placebo (tolbutamide dose 1.0 mg/min/dl).
Venous blood samples from the non-experimental arm were taken for the determination of insulin and C-peptide as well as for tolbutamide concentrations, both before and at the end of tolbutamide infusion. After each diazoxide infusion, venous blood samples from the experimental side were taken for the determination of local tolbutamide concentrations. At all these time points, the plasma glucose concentration was also measured. Glucose was measured immediately by an Accutrend glucose analyzer (type 1284851, Boehringer, Mann heim, Germany). Because of the long half-life, high protein binding (7, 23) and possible incorporation of SU derivatives in the plasma membrane (20) , randomization of placebo and tolbutamide was not possible because of carry-over effects.
For comparison, we also discuss here the data from identical studies with glibenclamide, which was given in a dose of 0.33 jxg/min/dl, and from studies with the newly developed SU derivative glimepiride, administered in a relatively high dose of 2.5 |ag/min/dl (5).
Humoral parameters
For determinations of local serum concentrations of the SU derivative, venous blood samples were collected in glass tubes without additives. After 20 minutes the blood was centrifuged at 3000 rpm for 10 minutes. Then serum was frozen at -2 0 D C. The drug concentrations in these serum samples were deter mined at the laboratories of Hoechst Marion Roussel, Frankfurt, Germany.
Insulin and C-peptide were measured in venous blood samples collected in chilled glass tubes coated with lithium-heparin. The blood was centrifuged at 3000 rpm for 10 minutes. Then plasma was frozen at -20"G In these samples, insulin and Cpeptide were determined in our laboratories using specific RIAs. C-Peptide was measured with a standard kit (D.P.C, Los Angeles, CA, USA) and insulin with a procedure using standard and tracer prepared from monocomponent human insulin (NOVO, Zoeterwoude, The Netherlands).
Calculations and statistics
Forearm vascular resistance (FVR) was calculated as the quotient of mean arterial pressure (MAP) and FBF. The ratio of experimental to non-experimental FBF was calculated to cor rect for systemic changes due to time or arousal in order to refer only to changes induced by local infusions (10 In the same manner, values for FVR and FBF-ratio were ob tained. The results were analyzed statistically by an analysis of variance (ANOVA) with repeated measures over all vasodilator dosages. A p-value of < 0.05 was considered statistically signif icant. Because of significant differences in baseline values, this analysis was performed on the percentage changes from base line for the FBF-ratio, but also for the FBF and FVR, followed by post-hoc t-tests when ANOVA was significant. Values pre sented are means ±SE unless indicated otherwise-
Results

Effects of sulfonylurea derivatives on vasodilator responses
During concomitant placebo infusion, the three dosages of di azoxide increased the FBF at the experimental arm dose-dependently by 99 ±24, 178 ±34 and 457 + 119% respectively. Changes at the contralateral arm were negligible: -4± 4, -13 ±5 and -23+5 % respectively. After equilibration, FBF returned to baseline levels, and the subsequent infusion in the presence of tolbutamide increased FBF by 61 ±14, 146+33 and 451 + SO% respectively. This second dose response curve was not different from the first one. Table 2 shows the absolute changes in FBF as well as in FVR for all dose steps. Fig.l illustrates the changes in FBF-ratio induced by diazoxide infusion into the brachial artery, both in the presence of placebo or tolbutamide. The right panel of this figure shows the percentage changes in the FBF-ratio during placebo and tolbutamide, and statistical analysis of these data did not reveal a significant difference, Table 3 shows the concentrations of glucose, insulin and C-peptide throughout the study. As a result of the regional infusion and the relatively low cumulative dose of tolbutamide, no in crease in systemic insulin or C-peptide concentrations and no fall in plasma glucose levels were observed during this study.
Changes in humoral parameters
During the second dose response curve, tolbutamide concen trations were sampled at the end of each diazoxide dose. These 15. local serum tolbutamide concentrations averaged 26±4[ig/ml, 17+2 f.tg/ml and 11 ±1 ¡ig/ml respectively (n « 12). At the end of the experiment the systemic tolbutamide concentration had accumulated to 5 ±0 jig/ml. 
FBF-Ratio
Discussion
The present study shows that the First generation SU derivative tolbutamide does not significantly attenuate the vasodilator response to the KA T P channel opener diazoxide in man. The in traarterial dosages of tolbutamide resulted in local concentra tions which were well within the therapeutic range as they occur systemically during regular treatment of NIDDM (18) . These observations argue against a significant effect of tolbu tamide treatment on vascular KA T P channels in humans.
In theory, the present observations may have been confounded by time effects. However, in our previous study on this issue we carefully performed time control studies, which showed that the repeat of diazoxide infusion in the time frame used in the current study resulted in an identical forearm vasodilator response (5).
When the effect of tolbutamide on the three vasodilator dosages to diazoxide is averaged to one mean value, a simple comparison can be made with the previously published data on glibenclamide and glimepiride (5) . For the sake of compari son, these data are depicted in 
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The relative absence of an interaction with vascular I<A T I> chan nels by tolbutamide can easily be explained by its weak phar macological effect, which also holds for the insulinotropic ef fect of this drug. As soon as metabolic regulation of NIDDM is insufficient with tolbutamide, the switch to a second genera tion SU-derivative is indicated. In this regard it is interesting that a switch to glimepiride will clearly improve metabolic reg ulation, whereas the function of the vascular I<A X P channels will not be impaired by this agent.
Patients with NIDDM are relatively often exposed to myocardila ischemia. Blockade of vascular I<A T P channels by gliben clamide has been shown to impair I<A T P channel-mediated pro tective effects (6,12). The UGDP-study suggested that tolbu tamide may have adverse cardiovascular effects (27) . This has also been suggested for glibenclamide (13, 24) . Our present study suggests that after acute administration, tolbutamide will probably not attenuate KA T P channel mediated cardiopro tective mechanisms. However, we can not exclude the possi bility that chronic exposure to tolbutamide, such as occurs during the treatment of NIDDM, may result in significant blockade of vascular KA T P channels in man. The present study must be interpreted as a call for further studies on the effects of chronic treatment with SU-derivatives on 1<A T P channel-me diated effects in patients with NIDDM.
Conclusions
We conclude that therapeutic concentrations of the first generation SU derivative tolbutamide are not able to attenuate vascular I<A T P channels in humans.
